Skip to main content

Table 1 Clinical characteristics of 154 patients with OSCC after definitive CCRT

From: Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy

Factors Training cohort
n (%)
Validation cohort
n (%)
p value
Age, years    0.087b
 Median (range) 61 (37–76) 58 (40–76)  
Sex    0.841c
 Male 77 (77.8%) 42 (76.4%)  
 Female 22 (22.2%) 13 (23.6%)  
Tumour location    0.325c
 Cervical 16 (16.2%) 13 (23.6%)  
 Upper 54 (54.5%) 31 (56.4%)  
 Middle 29 (29.3%) 11 (20.0%)  
T stagea    0.469c
 T2 11 (11.1%) 10 (18.2%)  
 T3 46 (46.5%) 24 (43.6%)  
 T4 42 (42.4%) 21 (38.2%)  
N stagea    0.655c
 N0 36 (36.4%) 22 (40.0%)  
 N1 63 (63.6%) 33 (60.0%)  
M stagea    0.668c
 M0 87 (87.9%) 47 (85.5%)  
 M1 12 (12.1%) 8 (14.5%)  
Clinical stagea    0.909c
 II stage 29 (29.3%) 16 (29.1%)  
 III stage 58 (58.6%) 31 (56.4%)  
 IV stage 12 (12.1%) 8 (14.5%)  
Chemotherapy regimen    0.559c
 RT with PF 91 (91.9%) 49 (89.1%)  
 RT with other regimens 8 (8.1%) 6 (10.9%)  
Dose regimen    0.102c
 2.2 Gy × 30 F 55 (55.6%) 23 (41.8%)  
 2.0 Gy × 32 F 44 (44.4%) 32 (58.2%)  
  1. OSCC, oesophageal squamous cell carcinoma; CCRT, concurrent chemoradiotherapy; AJCC, American Joint Committee on Cancer staging system (version 6.0th); RT, radiotherapy; PF, cisplatin and 5-fluorouracil
  2. aAmerican Joint Committee on Cancer (AJCC) staging system (version 6.0th)
  3. bp value was analysed using the independent samples t-test
  4. cp value was analysed using the chi-squared test